Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and Experimental Gastroenterology"
DOI: 10.2147/ceg.s351839
Abstract: Abstract In patients with gastrointestinal stromal tumors (GIST), systemic treatment after disease progression on imatinib is challenging. Sunitinib and regorafenib are approved in the second- and third-line setting, respectively, with activity against certain secondary mutations… read more here.
Keywords: stromal tumors; efficacy ripretinib; ripretinib; treatment ... See more keywords